Selective laser trabeculoplasty versus 0·5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial

Selective laser trabeculoplasty versus 0·5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial

Summary: Background: Glaucoma is a major cause of sight loss worldwide, with the highest regional prevalence and incidence reported in Africa. The most common low-cost treatment used to control glaucoma is long-term timolol eye drops. However, low adherence is a major challenge. We aimed to investi...

Full description

Bibliographic Details
Main Authors: Heiko Philippin, MD, Einoti Matayan, MMed, Karin M Knoll, MD, Edith Macha, Pharm Tech, Sia Mbishi, BSc, Andrew Makupa, MMed, Cristóvão Matsinhe, MMed, Vasco da Gama, MMed, Mario Monjane, MMed, Awum Joyce Ncheda, MMed, Francisco Alcides Mulobuana, MMed, Elisante Muna, MMed, Nelly Fopoussi, MMed, Gus Gazzard, ProfFRCOphth, Ana Patricia Marques, PhD, Peter Shah, ProfFRCOphth, David Macleod, PhD, William U Makupa, MMed, Matthew J Burton, ProfPhD
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:The Lancet Global Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2214109X2100348X

Internet

http://www.sciencedirect.com/science/article/pii/S2214109X2100348X

Similar Items